-
公开(公告)号:US07514475B2
公开(公告)日:2009-04-07
申请号:US11583499
申请日:2006-10-19
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: A61K31/137 , C07C205/04
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 is a C1-C6 alkyl, an amino, a (C1-C6 alkyl)amino, a di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and are a hydrogen or a C1-C6 alkyl; Arom is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl; wherein the substituted aryl is substituted at 1 to 5 positions and the substituted heteroaryl is substituted at 1 to 3 positions; wherein the heteroaryl is furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; and wherein the substituents of the substituted aryl and of the substituted heteroaryl are independently halogen, C1-C6 alkyl, halogeno C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C3 alkylenedioxy, C1-C7 alkanoyl, C2-C7 alkyloxycarbonyl, amino, C1-C7 alkanoylamino, hydroxyl, mercapto, cyano, nitro or carboxyl; A is an ethylene or propylene; Ra is a hydrogen, a C1-C6 alkyl or a C2-C6 alkenyl; E is a single bond, an oxygen, a sulfur or —NR4—, wherein R4 is a hydrogen or a C1-C7 alkanoyl; X1 and X2 are the same or different and are an oxygen or a sulfur, or a pharmacologically acceptable salt or ester thereof.
摘要翻译: 式(I)的化合物:其中R1是C1-C6烷基,氨基,(C1-C6烷基)氨基,二(C1-C6烷基)氨基或含氮饱和杂环; R2和R3相同或不同,为氢或C1-C6烷基; Arom是未取代或取代的芳基或未取代或取代的杂芳基; 其中取代的芳基在1至5个位置被取代,并且取代的杂芳基在1至3个位置被取代; 吡唑基,咪唑基,恶唑基,异恶唑基,噻唑基,异噻唑基,1,2,3-恶二唑基,吡喃基,吡啶基,哒嗪基,嘧啶基,吡嗪基或喹啉基;其中杂芳基为呋喃基,噻吩基,吡咯基, 并且其中取代的芳基和取代的杂芳基的取代基独立地为卤素,C 1 -C 6烷基,卤代C 1 -C 6烷基,C 1 -C 6烷氧基,C 1 -C 6烷硫基,C 1 -C 3亚烷基二氧基,C 1 -C 7烷酰基, C7烷氧基羰基,氨基,C1-C7烷酰基氨基,羟基,巯基,氰基,硝基或羧基; A是乙烯或丙烯; R a是氢,C 1 -C 6烷基或C 2 -C 6烯基; E是单键,氧,硫或-NR4-,其中R4是氢或C1-C7烷酰基; X1和X2相同或不同,为氧或硫,或其药理学上可接受的盐或酯。
-
公开(公告)号:US20080255095A1
公开(公告)日:2008-10-16
申请号:US11820218
申请日:2007-06-18
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: A61K31/55 , C07D333/22 , C07D215/38 , C07D263/34 , A61K31/50 , A61P25/28 , A61K31/4965 , C07D261/02 , C07D277/00 , C07D275/02
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 is C1-C6 alkyl, amino, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are hydrogen or C1-C6 alkyl; Arom is phenyl, idenyl, napthyl, phenanthrenyl, furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; A is C1-C6 alkylene; Ra is hydrogen, C1-C6 alkyl or C2-C6 alkenyl; E is a single bond, oxygen, sulfur or —NR4—, wherein R4 is hydrogen or C1-C7 alkanoyl; X1 and X2 are oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof.
摘要翻译: 式(I)的化合物:其中R 1是C 1 -C 6烷基,氨基,(C 1) (C 1 -C 6烷基)氨基或含氮饱和杂环基;(C 1 -C 6烷基)氨基, R 2和R 3是氢或C 1 -C 6烷基; 芳基是苯基,烯基,萘基,菲基,呋喃基,噻吩基,吡咯基,氮杂基,吡唑基,咪唑基,恶唑基,异恶唑基,噻唑基,异噻唑基,1,2,3-恶二唑基,吡喃基,吡啶基,哒嗪基,嘧啶基,吡嗪基或喹啉基。 A是C 1 -C 6亚烷基; R a是氢,C 1 -C 6烷基或C 2 -C 6烷基或C 2 -C 6 - 链烯基; E是单键,氧,硫或-NR 4 - ,其中R 4是氢或C 1 -C 7 烷酰基; X 1和X 2是氧或硫; 或其药理学上可接受的盐或酯。
-
公开(公告)号:US20090149444A1
公开(公告)日:2009-06-11
申请号:US12322173
申请日:2009-01-29
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: A61K31/55 , A61P25/28 , C07D223/16 , C07C271/44 , A61K31/27
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 represents a C1-C6 alkyl, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and represent hydrogen or a C1-C6 alkyl; Ra represents hydrogen, C1-C6 alkyl or C2-C6 alkenyl or together with R2 represents a C1-C3 alkylene; Arom represents a heteroaryl; A represents a C1-C6 alkylene; E represents a single bond, oxygen, sulphur or R4NR4—, wherein R4 is hydrogen or C1-C7 alkenoyl; X1 and X2 both represent oxygen; X2 is attached at the 3-position or the 4-position; or a pharmacologically acceptable salt or ester thereof. The compound has superior acetylcholinesterase inhibitory action and selective serotonin reuptake inhibitory action, and is useful for treating Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders.
摘要翻译: 式(I)的化合物:其中R1表示C1-C6烷基,(C1-C6烷基)氨基,二(C1-C6烷基)氨基或含氮饱和杂环; R2和R3相同或不同,表示氢或C1-C6烷基; R a表示氢,C 1 -C 6烷基或C 2 -C 6烯基或与R 2表示C 1 -C 3亚烷基; Arom表示杂芳基; A表示C1-C6亚烷基; E表示单键,氧,硫或R 4 NR 4 - ,其中R 4是氢或C 1 -C 7链烯酰基; X1和X2都代表氧; X2位于3位或4位; 或其药理学上可接受的盐或酯。 该化合物具有优异的乙酰胆碱酯酶抑制作用和选择性5-羟色胺再摄取抑制作用,可用于治疗阿尔茨海默病,抑郁症,亨廷顿氏舞蹈病,皮克病,迟发性运动障碍,强迫症或恐慌症。
-
公开(公告)号:US20070037795A1
公开(公告)日:2007-02-15
申请号:US11583499
申请日:2006-10-19
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: C07D333/22 , C07D215/38 , C07D277/00 , C07D275/02 , A61K31/55 , C07D263/34 , C07D261/02 , A61K31/50 , A61K31/4965
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (1): wherein R1 is a C1-C6 alkyl, an amino, a (C1-C6 alkyl)amino, a di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and are a hydrogen or a C1-C6 alkyl; Arom is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl; wherein the substituted aryl is substituted at 1 to 5 positions and the substituted heteroaryl is substituted at 1 to 3 positions; wherein the heteroaryl is furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; and wherein the substituents of the substituted aryl and of the substituted heteroaryl are independently halogen, C1-C6 alkyl, halogeno C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C3 alkylenedioxy, C1-C7 alkanoyl, C2-C7 alkyloxycarbonyl, amino, C1-C7 alkanoylamino, hydroxyl, mercapto, cyano, nitro or carboxyl; A is an ethylene or propylene; Ra is a hydrogen, a C1-C6 alkyl or a C2-C6 alkenyl; E is a single bond, an oxygen, a sulfur or —NR4—, wherein R4 is a hydrogen or a C1-C7 alkanoyl; X1 and X2 are the same or different and are an oxygen or a sulfur, or a pharmacologically acceptable salt or ester thereof.
-
公开(公告)号:US20070037793A1
公开(公告)日:2007-02-15
申请号:US11583404
申请日:2006-10-19
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: A61K31/55 , C07D223/16
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 is a C1-C6 alkyl group, an amino group, a (C1-C6 alkyl)amino group, a di(C1-C6 alkyl)amino group or a nitrogen-containing saturated heterocyclic group; R3 is a hydrogen atom or a C1-C6 alkyl group; Arom is an unsubstituted or substituted aryl group or an unsubstituted or substituted heteroaryl group; wherein the substituted aryl group is substituted at 1 to 5 positions and the substituted heteroaryl group is substituted at 1 to 3 positions; and wherein the substituents of the aryl group and of the heteroaryl group are independently selected from the group consisting of halogen atom, C1-C6 alkyl, halogeno C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C3 alkylenedioxy, C1-C7 alkanoyl, C2-C7 alkyloxycarbonyl, amino, C1-C7 alkanoylamino, hydroxyl, mercapto, cyano, nitro and carboxyl; A is a C1-C6 alkylene group; Ra together with R2 is a C2-C3 alkylene group containing a double bond; E is a single bond, an oxygen atom, a sulfur atom or a group of the formula: —NR4—, wherein R4 is a hydrogen atom or a C1-C7 alkanoyl group; X1 and X2 are the same or different and are an oxygen atom or a sulfur atom, or a pharmacologically acceptable salt or ester thereof.
-
公开(公告)号:US07504393B2
公开(公告)日:2009-03-17
申请号:US11583404
申请日:2006-10-19
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Hiroshi Kogen , Keiko Suzuki
IPC分类号: A61K31/55 , A61K31/4704 , C07D215/06 , C07D223/04
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 is a C1-C6 alkyl group, an amino group, a (C1-C6 alkyl)amino group, a di(C1-C6 alkyl)amino group or a nitrogen-containing saturated heterocyclic group; R3 is a hydrogen atom or a C1-C6 alkyl group; Arom is an unsubstituted or substituted aryl group or an unsubstituted or substituted heteroaryl group; wherein the substituted aryl group is substituted at 1 to 5 positions and the substituted heteroaryl group is substituted at 1 to 3 positions; and wherein the substituents of the aryl group and of the heteroaryl group are independently selected from the group consisting of halogen atom, C1-C6 alkyl, halogeno C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C3 alkylenedioxy, C1-C7 alkanoyl, C2-C7 alkyloxycarbonyl, amino, C1-C7 alkanoylamino, hydroxyl, mercapto, cyano, nitro and carboxyl; A is a C1-C6 alkylene group; Ra together with R2 is a C2-C3 alkylene group containing a double bond; E is a single bond, an oxygen atom, a sulfur atom or a group of the formula: —NR4—, wherein R4 is a hydrogen atom or a C1-C7 alkanoyl group; X1 and X2 are the same or different and are an oxygen atom or a sulfur atom, or a pharmacologically acceptable salt or ester thereof.
摘要翻译: 式(I)的化合物:其中R1是C1-C6烷基,氨基,(C1-C6烷基)氨基,二(C1-C6烷基)氨基或含氮饱和杂环 组; R3是氢原子或C1-C6烷基; Arom是未取代或取代的芳基或未取代或取代的杂芳基; 其中取代的芳基在1至5个位置被取代,取代的杂芳基在1至3个位置被取代; 并且其中芳基和杂芳基的取代基独立地选自卤素原子,C 1 -C 6烷基,卤代C 1 -C 6烷基,C 1 -C 6烷氧基,C 1 -C 6烷硫基,C 1 -C 3亚烷基二氧基, C 1 -C 7烷酰基,C 2 -C 7烷氧基羰基,氨基,C 1 -C 7烷酰氨基,羟基,巯基,氰基,硝基和羧基; A是C1-C6亚烷基; R a与R 2一起是含有双键的C 2 -C 3亚烷基; E是单键,氧原子,硫原子或式-NR4-基团,其中R4是氢原子或C1-C7烷酰基; X1和X2相同或不同,为氧原子或硫原子,或其药理学上可接受的盐或酯。
-
公开(公告)号:US07504437B2
公开(公告)日:2009-03-17
申请号:US10629108
申请日:2003-07-28
申请人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Keiko Suzuki
发明人: Kazuo Koyama , Shinji Marumoto , Narihiro Toda , Keiko Suzuki
IPC分类号: A61K31/136 , C07C211/03
CPC分类号: C07C219/30 , C07C271/44 , C07C323/20 , C07C323/25 , C07C333/04 , C07D213/64 , C07D213/68 , C07D215/20 , C07D317/58 , C07D333/38
摘要: A compound of the formula (I): wherein R1 represents C1–C6 alkyl, amino(C1–C6 alkyl)amino, di(C1–C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and represent hydrogen or C1–C6 alkyl; Ra represents C1–C6 alkyl or C2–C6 alkenyl or together with R2 represents a C1–C3 alkylene; Arom represents aryl or heteroaryl; A represents a C1–C6 alkylene; E represents a single bond, oxygen, sulfur or R4NR4—, wherein R4 is hydrogen or C1–C7 alkenoyl; X1 and X2 are the same or different and represent oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof. The compound has superior acetylcholinesterase inhibitory action and selective serotonin reuptake inhibitory action, and is useful for treating or preventing Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders.
摘要翻译: 式(I)的化合物:其中R1表示C1-C6烷基,氨基(C1-C6烷基)氨基,二(C1-C6烷基)氨基或含氮饱和杂环; R2和R3相同或不同,表示氢或C1-C6烷基; R a表示C 1 -C 6烷基或C 2 -C 6烯基或与R 2表示C 1 -C 3亚烷基; 芳基表示芳基或杂芳基; A表示C1-C6亚烷基; E表示单键,氧,硫或R 4 NR 4 - ,其中R 4是氢或C 1 -C 7链烯酰基; X1和X2相同或不同,代表氧或硫; 或其药理学上可接受的盐或酯。 该化合物具有优异的乙酰胆碱酯酶抑制作用和选择性5-羟色胺再摄取抑制作用,可用于治疗或预防阿尔茨海默病,抑郁症,亨廷顿舞蹈病,皮克病,迟发性运动障碍,强迫症或恐慌症。
-
8.
公开(公告)号:US20080153778A1
公开(公告)日:2008-06-26
申请号:US11973900
申请日:2007-10-09
申请人: Yasuyuki Ogawa , Ryo Okuyama , Satoshi Shibuya , Narihiro Toda , Zhaodan Cao , Zice Fu , Xiaolin Hao , Yong-Jae Kim , Leping Li , Sarah E. Lively , Mike Lizarzaburu , Hui Tian , Ming Yu
发明人: Yasuyuki Ogawa , Ryo Okuyama , Satoshi Shibuya , Narihiro Toda , Zhaodan Cao , Zice Fu , Xiaolin Hao , Yong-Jae Kim , Leping Li , Sarah E. Lively , Mike Lizarzaburu , Hui Tian , Ming Yu
IPC分类号: A61K31/715 , A61K31/155 , A61K31/4439 , A61P3/10 , C07D401/04 , A61K31/44
CPC分类号: C07D409/14 , C07D401/14 , C07D403/04 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
摘要翻译: 具有式I的化合物:其中A 1,A 2,L,V,W,R 1,R 2, >,R 3,R 4和R 5如本文所述,其组合物及其用于治疗或预防2型的用途 本文提供糖尿病和2型糖尿病相关病症。
-
公开(公告)号:US08222281B2
公开(公告)日:2012-07-17
申请号:US12893592
申请日:2010-09-29
申请人: Narihiro Toda , Masao Yoshida , Rieko Takano , Masahiro Inoue , Takeshi Honda , Koji Matsumoto , Ryutaro Nakashima
发明人: Narihiro Toda , Masao Yoshida , Rieko Takano , Masahiro Inoue , Takeshi Honda , Koji Matsumoto , Ryutaro Nakashima
IPC分类号: A61K31/44 , C07D211/94
CPC分类号: C07D207/325 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/275 , A61K31/343 , A61K31/40 , A61K31/4192 , A61K31/426 , A61K31/428 , A61K31/47 , A61K31/4741 , C07C59/66 , C07C59/72 , C07C205/34 , C07C205/37 , C07C217/76 , C07C229/42 , C07C255/54 , C07C311/29 , C07C317/22 , C07C2601/02 , C07C2602/08 , C07D215/22 , C07D249/04 , C07D277/24 , C07D277/64 , C07D307/83 , C07D491/048
摘要: To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ═C(R5)- or ═N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R1 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R2, R3, R4, and R5 may be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group. In this connection, the alkyl group moieties of R1 and R2 may be bonded to each other to form a 5- to 6-membered heterocyclic ring containing one oxygen atom.
摘要翻译: 找到具有优异活性和安全性的治疗剂和/或糖尿病预防剂等。 由以下通式(I)表示的化合物或其药理学上可接受的盐。 在该式中,X表示=(C)(R5) - 或= N-; Y表示-O-或-NH-; L表示键或可取代的C1-C3亚烷基; M表示可取代的C 3 -C 10环烷基,可取代的C 6 -C 10芳基或可取代的杂环基; R1表示C1-C6烷基,C3-C10环烷基,C1-C6卤代烷基,C2-C6烯基,C2-C6炔基,C1-C6脂肪族酰基,C1-C6烷氧基 C1-C6烷基或C6-C10芳基; R2,R3,R4和R5可以相同或不同,表示氢原子,卤素原子,C1-C3烷基,C1-C3卤代烷基,C1-C3烷氧基或硝基 组。 就此而言,R 1和R 2的烷基部分可以相互结合形成含有一个氧原子的5-至6-元杂环。
-
10.
公开(公告)号:US08022061B2
公开(公告)日:2011-09-20
申请号:US11973900
申请日:2007-10-09
申请人: Yasuyuki Ogawa , Ryo Okuyama , Satoshi Shibuya , Narihiro Toda , Zhaodan Cao , Zice Fu , Xiaolin Hao , Yong-Jae Kim , Leping Li , Sarah E. Lively , Mike Lizarzaburu , Hui Tian , Ming Yu
发明人: Yasuyuki Ogawa , Ryo Okuyama , Satoshi Shibuya , Narihiro Toda , Zhaodan Cao , Zice Fu , Xiaolin Hao , Yong-Jae Kim , Leping Li , Sarah E. Lively , Mike Lizarzaburu , Hui Tian , Ming Yu
IPC分类号: C07D403/04 , C07D417/14 , A61K31/506
CPC分类号: C07D409/14 , C07D401/14 , C07D403/04 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
摘要翻译: 具有式I的化合物:其中A1,A2,L,V,W,R1,R2,R3,R4和R5如本文所述,其组合物及其用于治疗或预防2型糖尿病和2型糖尿病 - 在此提供相关条件。
-
-
-
-
-
-
-
-
-